Haemophilus influenzae type b conjugate vaccine is highly effective in the Ugandan routine immunization program: a case-control study

2008 ◽  
Vol 13 (4) ◽  
pp. 495-502 ◽  
Author(s):  
Ellen Hyun-Ju Lee ◽  
Rosamund F. Lewis ◽  
Issa Makumbi ◽  
Adeodata Kekitiinwa ◽  
Tom D. Ediamu ◽  
...  
Keyword(s):  
Haemophilus Influenzae ◽  
Conjugate Vaccine ◽  
Case Control Study ◽  
Case Control ◽  
Haemophilus Influenzae Type ◽  
Haemophilus Influenzae Type B ◽  
Type B ◽  
Immunization Program ◽  
Routine Immunization Program ◽  
Control Study

scholarly journals Impact of Haemophilus Influenzae Type B Combination Vaccination on Asthma Symptoms and Pneumonia in 5-year-old Children in Rural Bangladesh: a Case-control Study and Comparison With a Previous Cross-sectional Study 

2020 ◽  
Author(s):  
HARUKO TAKEUCHI ◽  
S. M. Tafsir Hasan ◽  
Khalequ Zaman ◽  
Sayaka Takanashi ◽  
Samar Kumar Hore ◽  
...  
Keyword(s):  
Booster Dose ◽  
Case Control Study ◽  
Reduction Rate ◽  
Case Control ◽  
Haemophilus Influenzae Type ◽  
Haemophilus Influenzae Type B ◽  
Type B ◽  
Rural Bangladesh ◽  
History Of ◽  
Control Study

Abstract Background: Although the prevalence of bronchial asthma has been increasing worldwide since the 1970’s, the prevalence among 5-year-old children was significantly lower in 2016 than in 2001 in rural Bangladesh. We aimed to determine whether the Haemophilus influenzae type b (Hib) combination vaccination (without booster) started in 2009 contributed to this decrease.Methods: A case-control study was conducted among 1658 randomly selected 5-year-old children from Matlab, Bangladesh. Data on wheezing were collected using the International Study of Asthma and Allergies in Childhood questionnaire. The vaccination data were collected from the records of the Matlab Health and Demographic Surveillance System, while data on pneumonia were obtained from the clinical records of Matlab Hospital. Adjusted odds ratios (aORs) were calculated for the risk for wheezing. The reduction rate was calculated to determine the impact of the vaccination on pneumonia history between the present study and our previous study conducted in 2001 by using the following formula: (percentage of pneumonia cases in 2001 - percentage of pneumonia cases in 2016)/(percentage of pneumonia cases in 2001) times 100 (%).Results: Hib combination vaccination was a protecting factor against wheezing (aOR: 0.50; p = 0.010), while pneumonia at 1, 2, 3–4 years of age were risk factors for wheezing (aOR: 2.86, 3.19, 2.86; p = 0.046, 0.030, 0.030, respectively). The history of pneumonia was significantly lower in the 2016 study participants than those in 2001 both in the overall cohort and the wheezing group (paired t-test: p = 0.012, p < 0.001, respectively). Whereas the history of pneumonia decreased when the children grew older in the 2001 overall cohort, it peaked at the age of 2 years in 2016 wheezing group. The reduction rate decreased when children grew older in both the overall cohort and the wheezing group, however, it decreased faster in the wheezing group.Conclusions: Hib combination vaccination was a protective factor against wheezing in 0-year-old children. However, the effects of vaccination might have attenuated at the ages of 1-4 years, because no booster dose was administered. The addition of a booster dose might further decrease the prevalence of asthma and wheezing.

Sign in / Sign up

Export Citation Format

Share Document